Table of contents
February 2006 Volume 2 No 2
Top of page
Editorial
Top of page
Viewpoint
Which target blood pressure is optimal for renoprotection?
Marcin Adamczak,
Jerzy Chudek
and
Andrzej Wi
cek
doi:10.1038/ncpneph0092 | Full Text | PDF (101K)
Top of page
Research Highlights
Nephrologists perform more accurate urinalysis than clinical laboratory personnel
60Ruboxistaurin: a promising new treatment for use in diabetic nephropathy
60Using serum prealbumin concentration to monitor risk in end-stage renal disease patients
60Prolonged waiting times should not preclude kidney transplantation
61Post-transplantation recurrence of FSGS prevented by pre-emptive plasmapheresis
61MMF and gastrointestinal complaints: impact on transplant outcomes and costs
62ANCA-associated small vessel vasculitis: treatment with mycophenolate mofetil
62Esomeprazole for cysteamine-induced gastrointestinal symptoms in children with cystinosis
63Top of page
Practice Points
Is there a correlation between atherosclerosis and renal resistive indices in kidney transplant recipients?
64Does extended-release somatostatin slow the growth of renal cysts in autosomal-dominant polycystic kidney disease?
66Can an algorithm based on dipstick urine protein and urine specific gravity accurately predict proteinuria?
68Do implantable cardioverter-defibrillators improve survival in dialysis patients after cardiac arrest?
70Does enzyme replacement therapy improve symptoms of Fabry disease in patients undergoing dialysis?
72Which index is optimal for assessment of baseline comorbidities in kidney transplant recipients?
74Does statin therapy improve cardiovascular outcomes in patients with type 2 diabetes receiving hemodialysis?
76Top of page
Reviews
Drug Insight: safety of intravenous iron supplementation with sodium ferric gluconate complex
92doi:10.1038/ncpneph0068 | Full Text | PDF (234K)
Mechanisms of Disease: fibroblasts—a new look at an old problem
101doi:10.1038/ncpneph0093 | Full Text | PDF (352K)
Top of page
Case Study
Lactic acidosis in an HIV-infected patient receiving highly active antiretroviral therapy
109doi:10.1038/ncpneph0102 | Full Text | PDF (166K)
